Jaime Y. Kim

ORCID: 0000-0003-1266-1917
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Bioinformatics and Genomic Networks
  • Epigenetics and DNA Methylation
  • Bladder and Urothelial Cancer Treatments
  • Computational Drug Discovery Methods
  • Molecular Biology Techniques and Applications
  • Cancer Genomics and Diagnostics
  • Prostate Cancer Treatment and Research
  • Adipose Tissue and Metabolism
  • Mathematical Biology Tumor Growth
  • Cancer-related molecular mechanisms research
  • Radiation Therapy and Dosimetry
  • Mitochondrial Function and Pathology
  • Protein Degradation and Inhibitors
  • Cancer, Hypoxia, and Metabolism
  • Pharmacogenetics and Drug Metabolism
  • Statistical Methods in Clinical Trials
  • Health Systems, Economic Evaluations, Quality of Life
  • RNA modifications and cancer
  • Cancer, Stress, Anesthesia, and Immune Response
  • Estrogen and related hormone effects
  • Immunotherapy and Immune Responses
  • PARP inhibition in cancer therapy
  • Virus-based gene therapy research
  • Metabolism, Diabetes, and Cancer
  • Animal Genetics and Reproduction

Columbia University
2022-2024

Columbia University Irving Medical Center
2021-2023

Mitochondria provide the first line of defense against tumor-promoting effects oxidative stress. Here we show that prostate-specific homeoprotein NKX3.1 suppresses prostate cancer initiation by protecting mitochondria from Integrating analyses genetically engineered mouse models, human cells, and organotypic cultures, find that, in response to stress, is imported via chaperone protein HSPA9, where it regulates transcription mitochondrial-encoded electron transport chain (ETC) genes, thereby...

10.1158/2159-8290.cd-20-1765 article EN Cancer Discovery 2021-04-23

Abstract Prioritizing treatments for individual patients with cancer remains challenging, and performing coclinical studies using patient-derived models in real time is often unfeasible. To circumvent these challenges, we introduce OncoLoop, a precision medicine framework that predicts drug sensitivity human tumors their preexisting high-fidelity (cognate) model(s) by leveraging perturbation profiles. As proof of concept, applied OncoLoop to prostate genetically engineered mouse (GEMM)...

10.1158/2159-8290.cd-22-0342 article EN Cancer Discovery 2022-11-14

Abstract To study the progression of bladder cancer from non–muscle-invasive to muscle-invasive disease, we have developed a novel toolkit that uses complementary approaches achieve gene recombination in specific cell populations urothelium vivo, thereby allowing us generate new series genetically engineered mouse models (GEMM) cancer. One method is based on delivery adenoviruses express Cre recombinase selected types urothelium, and second transgenic drivers which activation inducible...

10.1158/0008-5472.can-21-1254 article EN Cancer Research 2021-09-01

Although localized prostate cancer is relatively indolent, advanced manifests with aggressive and often lethal variants, including neuroendocrine (NEPC). To identify drivers of cancer, we leveraged

10.1101/2024.08.24.609538 preprint EN bioRxiv (Cold Spring Harbor Laboratory) 2024-08-26

Abstract At present, prioritizing cancer treatments at the individual patient level remains challenging, and performing co-clinical studies using patient-derived models in real-time is often not feasible. To circumvent these challenges, we introduce OncoLoop, a precision medicine framework to predict validate drug sensitivity human tumors their pre-existing high-fidelity ( cognate ) model(s) by leveraging perturbational profiles of clinically-relevant oncology drugs. As proof-of-concept,...

10.1101/2022.02.11.479456 preprint EN bioRxiv (Cold Spring Harbor Laboratory) 2022-02-14

<div>Abstract<p>To study the progression of bladder cancer from non–muscle-invasive to muscle-invasive disease, we have developed a novel toolkit that uses complementary approaches achieve gene recombination in specific cell populations urothelium <i>in vivo</i>, thereby allowing us generate new series genetically engineered mouse models (GEMM) cancer. One method is based on delivery adenoviruses express Cre recombinase selected types urothelium, and second transgenic...

10.1158/0008-5472.c.6513832.v1 preprint EN 2023-03-31

<div>Abstract<p>Mitochondria provide the first line of defense against tumor-promoting effects oxidative stress. Here we show that prostate-specific homeoprotein NKX3.1 suppresses prostate cancer initiation by protecting mitochondria from Integrating analyses genetically engineered mouse models, human cells, and organotypic cultures, find that, in response to stress, is imported via chaperone protein HSPA9, where it regulates transcription mitochondrial-encoded electron transport...

10.1158/2159-8290.c.6549455.v1 preprint EN 2023-04-03

<div>Abstract<p>Prioritizing treatments for individual patients with cancer remains challenging, and performing coclinical studies using patient-derived models in real time is often unfeasible. To circumvent these challenges, we introduce OncoLoop, a precision medicine framework that predicts drug sensitivity human tumors their preexisting high-fidelity (cognate) model(s) by leveraging perturbation profiles. As proof of concept, applied OncoLoop to prostate genetically engineered...

10.1158/2159-8290.c.6549772.v1 preprint EN 2023-04-04
Coming Soon ...